gene was just the latest-discovered link between the two diseases; Parkin mutations cause up to half of early-onset hereditary cases of Parkinson's disease. Another earlyonset Parkinson's gene, DJ-1, has been implicated in cancer, and a third gene, LRRK2, has features that strongly hint at cancerlike effects. Epidemiological studies show that Parkinson's patients have less risk of most cancers but increased risk for some. These mysterious connections have raised hopes that studying the biology of one disease will lead to treatments for the other. Such research, barely begun, could eventually solve the mystery and explain what dead neurons have in common with cells that refuse to die.
Neuron Protector and Tumor Suppressor N E W S
interfered with the protein's ability to ubiquitinate (by attaching small ubiquitin proteins as tags) and to degrade cyclin E, a critical component of the cell cycle. Cyclin E levels went up, and the cells began cycling and dividing faster. Chan speculates that, in Parkinson's disease, similar Parkin mutations lead to cyclin E buildup, which causes dopaminergic neurons to try to divide -a catastrophic development in these cells. "Because they're terminally differentiated, they cannot divide, and then they die," he said.
Divide and Conquer, or Die Trying
In 2003 Staropoli had reported cyclin E accumulation in Parkin-defi cient primary neurons and speculated that loss of Parkin caused dopaminergic neurons to reenter the cell cycle and die. But other ideas about Parkin loss in Parkinson's disease eclipsed the cyclin E story. The other theories ranged from wholesale derangement of protein degradation -a cellular "garbage strike" -to the excessive buildup of the neurotransmitter glutamate at the synapse, or excitotoxicity, leading to cell death, to the autoconsumption of mitochondria, known as mitophagy. But the Chan study, together with two other reports last year, reaffi rms cyclin E as a major suspect.
"I do feel a certain amount of vindication," said Staropoli. He and Chan didn't rule out other mechanisms of cell death from Parkin loss, but Staropoli speculated that they might converge downstream, all leading to the kick-starting of the cell cycle in neurons followed by cell death. "Maybe cyclin E or another cell cycle regulatory protein is at the nexus of this converging pathway," Staropoli said.
The In cancer, Parkin was already a suspected tumor suppressor gene because it resides on the long arm of chromosome 6, a segment of which has long been known to be altered or deleted in a wide variety of human cancers. In their recent Nature Genetics article In both diseases "the cell cycle is being engaged in an aberrant manner," observed Chan. "Gaining insight into the function of Parkin in cancer may potentially identify novel targets of therapy that may be useful in both cases." Chan's lab is now looking for Parkin loss in other cancer types, screening for other ubiquitination targets of Parkin, and crossing Parkin-knockout mice with mice lacking other tumor suppressor genes to work out the exact role that Parkin plays in cancer.
LRRKing in the Wings
The other Parkinson's gene solidly linked to cancer is DJ-1. DJ-1 was cloned in 1997 as an oncogene, and 6 years later the mutant form was found to cause early-onset Parkinson's disease in families, although it's much rarer than Parkin. The role of DJ-1, a molecular chaperone and sensor of oxidative So far LRRK2 links to cancer are only indirect and suggestive. Like many key cancer genes, LRRK2 codes for a kinase -it can transfer a phosphate group from ATP to a downstream substrate to activate it. And, like the ras oncogene, it is also a GTPase, in that it can bind either of the guanine nucleotides, GDP or GTP; such binding determines its activation state and its ability to send an excitatory signal to downstream targets. LRRK2 is the only known protein (besides LRRK1) to have both a kinase domain and a ras-like GTPase domain. (This fi nding has made it an attractive drug target in Parkinson's disease, because there are multiple places for small-molecule compounds to bind.) LRRK2 may function in the mitogen-activated protein kinase pathway, which is important for cell survival. One more cancerlike feature is the most common Parkinson's-related LRRK2 protein alteration: It's in the same structural position as the alteration in BRAF kinase that drives about half of all cases of malignant melanoma.
Whether LRRK2 has anything to do with melanoma or any other cancer is unknown. But because so many Ashkenazi Jews and Arab Berbers with Parkinson's disease have the gene, large epidemiological studies looking at cancer incidence are now under way. For example, Jankovic and colleague Rivka Inzelberg, M.D., of Tel Aviv University in Israel are completing a large study looking at cancer in Israeli Ashkenazi Jews who carry the mutant LRRK2 gene. "There is some speculation that there is going to be a strong link between cancer and LRRK2 mutations in this population," said West.
Mostly, the Parkinson's -cancer story remains to be written. The association is fi rm, but mechanistic fi ndings are sketchy, largely speculative and sometimes contradictory. "You're not going to build a unifi ed hypothesis to describe the link without understanding the specifi c biochemical . . . mechanisms," said West. Other researchers agree the knowledge gaps are wide but inviting. "There are a lot of interesting hints and clues," said Jankovic. "And I think we just need to connect the dots."
